Chelation therapy in the JCR:LA-cp rat: Experimental assessment of a putative antiatherosclerotic treatment

Clinical and Investigative Medicine

Volumn 23, Issue 2, 2000, Pages 124-131

  O'Brien, Sheila F ^a   Kelly, Sandra E ^b   Dolphin, Peter J ^c   Russell, James C ^b  

^a CANADIAN BLOOD SERVICES   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

^c DALHOUSIE UNIVERSITY   (Canada)

Author keywords

Atherosclerosis; Cardiovascular diseases; Chelation therapy; Edetic acid; Rats; Research

Indexed keywords

CALCIUM; EDETIC ACID; MAGNESIUM;

AORTA ARCH; ARTICLE; ATHEROSCLEROSIS; BLOOD ANALYSIS; BONE MINERAL; CHELATION THERAPY; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DRUG EFFECT; HEART MUSCLE ISCHEMIA; HYPERINSULINEMIA; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; MACROPHAGE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SCANNING ELECTRON MICROSCOPY; TRIACYLGLYCEROL BLOOD LEVEL; VASCULAR DISEASE;

ANIMALS; AORTA, THORACIC; ARTERIOSCLEROSIS; BONE AND BONES; CALCIUM; CHELATION THERAPY; COMPLEMENTARY THERAPIES; DISEASE MODELS, ANIMAL; EDETIC ACID; ENDOTHELIUM, VASCULAR; INSULIN RESISTANCE; LIPIDS; MACROPHAGES; MAGNESIUM; MALE; MICROSCOPY, ELECTRON, SCANNING; OBESITY; PROSPECTIVE STUDIES; RATS; RATS, MUTANT STRAINS; TRIGLYCERIDES;

EID: 0033938170     PISSN: 0147958X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. 1. Grier MT, Meyers DG. So much writing, so little science: a review of 37 years of literature on edetate sodium chelation therapy. Ann Pharmacother 1993;27: 1504-9.
2. 2. Rathmann KL, Golightly LK. Chelation therapy of atherosclerosis. Drug Intell Clin Pharm 1984;18:1000-3.
3. 3. Chappell LT, Wilson J. Chelation therapy for vascular disease. Circulation 1999;99:164-7.
4. 4. von Schacky C, Angerer P, Kothny W, Theisen K, Mudra H. The effect of dietary omega-3 fatty acids on coronary atherosclerosis. A randomized, double-blind placebo-controlled trial. Ann Intern Med 1999;130: 554-62.
5. 5. Brown MS, Goldstein JL. Heart attacks: Gone with the century? [editorial]. Science 1996;272:629.
6. 6. Steiner G. Hyperinsulinemia and hypertriglyceridemia. J Intern Med 1994;236(Suppl):23-6.
7. 7. Després JP, Lamarche B, Mauriege P, Cantin B, Dagenais GR, Moorjani S, et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 1996-334:952-7.
8. 8. Lamarche B, Lewis GF. Atherosclerosis prevention for the next decade: risk assessment beyond low density lipoprotein cholesterol [review]. Can J Cardiol 1998; 14:841-51.
9. 9. Stary HC. Changes in components and structure of atherosclerotic lesions developing from childhood to middle age in coronary arteries [review]. Basic Res Cardiol 1994;89(Suppl):17-32.
10. 10. Richardson M, Hadcock SJ, Hatton MW, Winocour PD, Hatton MW. Proteoglycan alterations in the aortic intima-media of alloxan diabetic rabbits: an ultrastructural and biochemical study. Exper Mol Pathol 1995; 62:145-59.
11. 11. Richardson M, Schmidt AM, Graham SE, Achen B, DeReske M, Russell JC. Vasculopathy and insulin resistance in the JCR:LA-cp rat. Atherosclerosis 1998; 138:135-46.
12. 12. McGillem MJ, Mancini GB. Inefficiency of EDTA chelation therapy for coronary atherosclerosis [letter]. N Engl J Med 1988;318:1618-9.
13. 13. Wirebaugh SR, Geraets DR. Apparent failure of edetic acid chelation therapy for the treatment of coronary atherosclerosis. DICP 1990;24:22-5.
14. 14. Koletsky S. Obese spontaneously hypertensive rats: a model for the study of atherosclerosis. Exp Mol Pathol 1973;19:52-60.
15. 15. Koletsky S. Pathological findings and laboratory data in a new strain of obese hypertensive rats. Am J Pathol 1975;80:129-42.
16. 16. Wu-Peng XS, Chua SC Jr, Okada N, Liu S-M, Nicolson M, Leibel RL. Phenotype of the obese Koletsky (f) rat due to Tyr763Stop mutation in the extracellular domain of the leptin receptor (Lepr). Diabetes 1997;46:513-8.
17. 17. Russell JC, Bar-Tana J, Shillabeer G, Lau DC, Richardson M, Wenzel LM, et al. Development of insulin resistance in the JCR:LA-cp rat: role of triacylglycerols and effects of MEDICA 16. Diabetes 1998; 47:770-8.
18. 18. Dolphin PJ, Stewart B, Amy RM, Russell JC. Serum lipids and lipoproteins in the atherosclerosis prone LA/N-corpulent rat. Biochim Biophys Acta 1987;919: 140-8.
19. 19. Russell JC, Koeslag DG, Amy RM, Dolphin PJ. Plasma lipid secretion and clearance in hyperlipidemic JCR:LA-corpulent rats. Arteriosclerosis 1989;9:869-76.
20. 20. Russell JC, Amy RM. Early atherosclerotic lesions in a susceptible rat model: the LA/N-corpulent rat. Atherosclerosis 1986;60:119-29.
21. 21. Russell JC, Amy RM, Graham SE, Dolphin PJ, Wood GO, Bar-Tana J. Inhibition of atherosclerosis and myocardial lesions in the JCR:LA-cp rat by β,β′-tetramethylhexadecanedioic acid (MEDICA 16). Arterioscler Thromb Vasc Biol 1995;15:918-23.
22. 22. Harris WE, Kratovil B. An introduction to chemical analysis. Philadelphia: Saunders College Publishing; 1981.
23. 23. Russell JC, Graham SE, Dolphin PJ, Amy RM, Wood GO, Brindley DN. Antiatherogenic effects of long-term benfluorex treatment in male insulin resistant JCR:LA-cp rats. Atherosclerosis 1997;132:187-97.
24. 24. Russell JC, Dolphin PJ, Graham SE, Amy RM. Cardioprotective and hypolipidemic effects of nisoldipine in the JCR:LA-cp rat. J Cardiovasc Pharmacol 1997;29:586-92.
25. 25. Vance JE, Russell JC. Hypersecretion of VLDL, but not HDL, by hepatocytes from the JCR:LA-corpulent rat. J Lipid Res 1990;31:1491-501.
26. 26. Russell JC, Graham SE, Dolphin PJ, Brindley DN. Effects of benfluorex on serum triacylglycerols and insulin sensitivity in the corpulent rat. Can J Physiol Pharmacol 1996;74:879-86.
27. 27. Russell JC, Graham S, Stewart B, Dolphin PJ. Sexual dimorphism in the metabolic response to the calcium channel antagonists, diltiazem and clentiazem, by hyperlipidemic JCR:LA-cp rats. Biochim Biophys Acta 1995;1258:199-205.
28. 28. Lopaschuk GD, Russell JC. Myocardial function and energy substrate metabolism in the insulin-resistant JCR:LA-corpulent rat. J Appl Physiol 1991;71:1302-8.
29. 29. Oliver LD, Mehta R, Sarles HE. Acute renal failure following administration of ethylenediaminetetraacetic acid (EDTA). Texas Med 1984;80:40-2.
30. 30. Russell JC, Dolphin PJ, Graham SE, Amy RM, Brindley DN. Improvement of insulin sensitivity and cardiovascular outcomes in the JCR:LA-cp rat by D-fenfluramine. Diabetohgia 1998;41:380-9.
31. 31. Russell JC, Graham SE, Dolphin PJ, Amy RM, Wood GO, Brindley DN. Antiatherogenic effects of long-term benfluorex treatment in male insulin resistant JCR:LA-cp rats. Atherosclerosis 1997;132:187-97.